Advances in DNA and mRNA-Based Strategies for Cancer Immunotherapy: Volume 165. This item is unavailable.Advances in DNA and mRNA-Based Strategies for Cancer Immunotherapy: Volume 165

• Presents current developments and comprehensive reviews in immunology
• Provides the latest in a longstanding and respected serial on the subject matter
• Focuses on recent advances in the field of immunology

Arun Kumar Singh is Assistant Professor in the Department of Pharmacy at Vivekanand Global University, India. His teaching and research activities span pharmaceutical sciences and a range of interdisciplinary fields, including nanoformulation, cancer biology, artificial intelligence, machine learning, blockchain technology, the Internet of Things, big data analytics, and neuroscience. He has contributed to scholarly publishing through authorship and editorial work and has participated in research and academic initiatives that integrate emerging technologies with healthcare and pharmaceutical applications. His interests focus on advancing innovative approaches to drug delivery, biomedical research, and technology-enabled solutions for healthcare challenges.

Neeraj Mishra is Professor and Head of the Department of Pharmaceutics at the Amity Institute of Pharmacy, Amity University Madhya Pradesh, Gwalior, India. His academic work focuses on novel drug delivery systems, including localized, targeted, and controlled delivery approaches using nanocarrier and microparticle-based technologies. His research interests encompass therapies for cancer and neurodegenerative disorders, and he has extensive experience in teaching, research supervision, and scholarly publishing. He has also contributed to innovation in pharmaceutical sciences through intellectual property development and collaborative academic activities. Through his research and educational initiatives, he supports the advancement of drug delivery strategies and pharmaceutical research.

Dr. Sumel Ashique has been working as an assistant professor at the Department of Pharmaceutical Technology, School of Health and Medical Sciences, Adamas University, West Bengal, India. He has 5 years of teaching experience. He has achieved 100+ publications in international and national accredited reputed journals. He has expertise in drug delivery, nanotechnology, and targeted treatment strategies. Recently, he was honored to be in the World’s Top 2% Scientists by prestigious Stanford University, CA, United States, and Elsevier in 2025.

Pranav Kumar Prabhakar is Professor and Head of the Department of Biotechnology, School of Engineering and Technology, Nagaland University, Kohima, India. His research focuses on understanding molecular mechanisms involved in metabolic disorders, particularly diabetes, and on developing strategies for oral insulin delivery using natural products and biotechnology-based approaches. He is actively involved in research, academic mentoring, peer review, and editorial activities within the biomedical and biotechnology fields. His professional interests include translational research, signaling pathways associated with metabolic diseases, and the application of biotechnology to improve therapeutic outcomes. He contributes to scientific and academic initiatives that support advancements in biotechnology and healthcare research.